Fulcrum’s stumble comes after three different sickle cell therapies were discontinued across the industry on Wednesday and Thursday. Novartis cut an Intellia-partnered ex vivo therapy, Graphite ...

Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics ... a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET A live ...

Although Fulcrum Therapeutics has shed US$304m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns. Because Fulcrum ...